文献速递肿瘤 PET/CT核素与放射性配体治疗

质子治疗后FDG高摄取局灶性肝脏反应:一例原发性食管腺癌患者

FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma.
PubMed 文献 · Clin Nucl Med · 2018-01-01

一名25岁IgA缺乏男性胃食管交界腺癌患者接受2个月化疗和质子治疗后18天复查PET/CT,左肝叶出现2个新发FDG摄取增高灶,考虑放射损伤而非新发转移;2周后增强MRI显示肝内低强化及T1/T2低信号、无弥散受限,后续FDG PET/CT和MRI显示病灶消退,确诊急性放射损伤。

要点

  • 质子治疗后18天PET/CT左肝叶新发2个FDG高摄取灶,考虑放射损伤而非转移。
  • 2周后增强MRI显示对应主导FDG高摄取灶呈低强化、T1/T2低信号、无弥散受限。
  • 后续FDG PET/CT和MRI显示肝内病灶消退,确诊急性放射损伤。

核心结论

  • 质子治疗后短期出现的新发FDG高摄取肝灶可代表急性放射损伤而非新发转移,随访影像中病灶消退可确诊。

研究设计与样本

  • 病例报告:一名25岁IgA缺乏男性胃食管交界腺癌患者,接受2个月化疗和质子治疗。

主要发现

  • 质子治疗后18天复查PET/CT显示左肝叶2个新发FDG摄取增高灶,倾向放射损伤而非新发转移。
  • 2周后增强MRI显示肝内低强化和T1/T2低信号,无弥散受限,与主导FDG高摄取灶对应。
  • 后续FDG PET/CT和MRI显示肝内病灶消退,确诊急性放射损伤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 25-year-old man with IgA deficiency was treated with 2 months of chemotherapy and proton therapy for gastroesophageal junction adenocarcinoma. Restaging PET/CT 18 days posttherapy demonstrated 2 new foci of increased FDG uptake in the left hepatic lobe, which were favored to represent radiation injury as opposed to new metastases. Follow-up MRI with contrast 2 weeks later demonstrated hypoenhancement and T1/T2 hypointensity in the liver, without restricted diffusion, which correlated with the dominant FDG-avid focus. The hepatic lesions resolved on subsequent FDG PET/CT and MRI studies, confirming the diagnosis of acute radiation injury.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ahmed HS, Pantel AR, Metz JM, et al. FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma. Clin Nucl Med. 2018. PMID: 29561521. doi:10.1097/RLU.0000000000002035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。